Inhibition of TLR9-NF-κB-mediated sterile inflammation improves pressure overload-induced right ventricular dysfunction in rats

Cardiovasc Res. 2019 Mar 1;115(3):658-668. doi: 10.1093/cvr/cvy209.

Abstract

Aims: Recent accumulating evidence suggests that sterile inflammation plays a crucial role in the progression of various cardiovascular diseases. However, its contribution to right ventricular (RV) dysfunction remains unknown. The aim of this study was to elucidate whether toll-like receptor 9 (TLR9)-NF-κB-mediated sterile inflammation plays a critical role in the pathogenesis of RV dysfunction.

Methods and results: We performed main pulmonary artery banding (PAB) in rats to induce RV pressure overload and dysfunction. On Day 14 after PAB, the pressure overload impaired RV function as indicated by increased RV end-diastolic pressure concomitant with macrophage infiltration and fibrosis, as well as maximal activation of NF-κB and TLR9. Short-term administration (days 14-16 after PAB) of a specific TLR9 inhibitor, E6446, or an NF-κB inhibitor, pyrrolidine dithiocarbamate (PDTC) significantly attenuated NF-κB activation. Furthermore, long-term administration of E6446 (treatment: days 14-28) or PDTC (prevention: days -1 to 28; treatment: days 14 to 28) improved RV dysfunction associated with mitigated macrophage infiltration and fibrosis in right ventricle and decreased serum brain natriuretic peptide levels.

Conclusion: Inhibition of TLR9-NF-κB pathway-mediated sterile inflammation improved PAB-induced RV dysfunction in rats. This pathway plays a major role in the progression of pressure overload-induced RV dysfunction and is potentially a novel therapeutic target for the disorder.

Keywords: NF-κB; Pressure overload; RV dysfunction; Sterile inflammation; TLR9.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-Inflammatory Agents / pharmacology*
  • Fibrosis
  • Hypertrophy, Right Ventricular / drug therapy
  • Hypertrophy, Right Ventricular / metabolism
  • Hypertrophy, Right Ventricular / physiopathology
  • Inflammation / metabolism*
  • Inflammation / prevention & control
  • Inflammation Mediators / antagonists & inhibitors*
  • Inflammation Mediators / metabolism
  • Macrophages / drug effects
  • Macrophages / metabolism
  • Male
  • NF-kappa B / antagonists & inhibitors*
  • NF-kappa B / metabolism
  • Pyrrolidines / pharmacology*
  • Rats, Sprague-Dawley
  • Signal Transduction
  • Thiocarbamates / pharmacology*
  • Toll-Like Receptor 9 / antagonists & inhibitors*
  • Toll-Like Receptor 9 / metabolism
  • Ventricular Dysfunction, Right / drug therapy*
  • Ventricular Dysfunction, Right / metabolism
  • Ventricular Dysfunction, Right / physiopathology
  • Ventricular Function, Right*
  • Ventricular Pressure*
  • Ventricular Remodeling / drug effects

Substances

  • Anti-Inflammatory Agents
  • Inflammation Mediators
  • NF-kappa B
  • Pyrrolidines
  • Thiocarbamates
  • Tlr9 protein, rat
  • Toll-Like Receptor 9
  • pyrrolidine dithiocarbamic acid